IRF3 and Zika virus infectious disease: Here, we did not observe any differences in clinical signs nor in plasma viral loads between B6 and B6-Irf3 KO mice (pre-treated or not with the MAR1-5A3 antibody), consistently with a previous study that reported neither mortality, nor body weight loss after ZIKV infection [10].